Integrum initiates a strategic review process to accelerate growth

Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that its Board of Directors has initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™ Implant System.

Integrum has developed and markets the OPRA™ Implant System, an advanced prosthesis fixation system for individuals with mobility challenges due to limb amputation. Integrum’s implant solution is surgically inserted into the patient's skeleton – providing greatly increased functionality and significantly fewer complications than conventional socket prostheses. As a next step in revolutionizing the prosthesis market, Integrum is developing the e-OPRA^TM Implant System – the world’s first mind-controlled robot prosthesis capable of transmitting sensory feedback.

Integrum is experiencing rapid growth of its business and recently reported its highest quarterly sales revenue ever. The long-term goal is to establish OPRA^TM Implant Systems as the worldwide standard of care for individuals with mobility challenges.

The strategic review aims to ensure that the global roll-out of Integrum’s implant systems is conducted most efficiently, in the interest of both patients and shareholders. As part of the process, the Board will consider a full range of strategic alternatives, including mergers or other business combinations, strategic investments, sale of all or a portion of the company’s assets, corporate sale, or other significant transactions.

“By providing cutting-edge solutions, Integrum has the potential to transform the lives of its implant system users. Over the last years, we have made significant progress in establishing the OPRA^TM Implant System in the U.S. and several other geographies. Still, there is an enormous untapped potential for our innovative solutions, and we look forward to evaluating all options to expedite future growth, “comments Bengt Sjöholm, chairman of the Board.

As part of the strategic review process, Integrum has engaged Incentrum – a global merchant bank based in New York City – as its financial advisor to advise the company regarding this broad and comprehensive review and analysis of strategic alternatives.

Integrum has not set a timetable for completion of the process and does not plan to provide any updates on developments unless and until the company executes a definitive agreement with respect thereto or the Board determines to conclude the strategic review. While the company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.